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Abstract
Introduction The discovery of activating KIT and PDGFRα mutations in gastrointestinal stromal tumors (GISTs) represented
a milestone as it allowed clinicians to use tyrosine kinase inhibitors, like imatinib, to treat this sarcoma. Although surgery
remains the only potentially curative treatment, patients who undergo complete resection may still experience local recurrence
or distant metastases. Therapeutic strategies that combine surgical resection and adjuvant imatinib may represent the best
treatment to maximize patient outcomes. In addition to the use of imatinib in the adjuvant and metastatic settings, neoadjuvant
imatinib, employed as a cytoreductive therapy, can decrease tumor volume, increase the probability of complete resection, and
may reduce surgery-related morbidities. Thus, selected patients with metastatic disease may be treated with a combination of
preoperative imatinib and metastasectomy. However, it is critical that patients with GIST be evaluated by a multidisciplinary
team to coordinate surgery and targeted therapy in order to maximize clinical outcomes.
Discussion Following a systematic literature review, we describe the presentation, diagnosis, and treatment of GIST, with a
discussion of the risk assessment for imatinib therapy. The application of surgical options, combined with adjuvant/neoadjuvant or
perioperative imatinib, and their potential impact on survival for patients with primary, recurrent, or metastatic GISTare discussed.
Keywords Gastrointestinal stromal tumor . GIST .
Imatinib . Tyrosine kinase inhibitor . Outcomes
Introduction
Gastrointestinal stromal tumors (GISTs) are the most com-
mon type of mesenchymal tumors of the gastrointestinal
tract. The estimated prevalence of GIST is 12–20 cases per
million, with an estimated annual incidence of 6,000 cases in
the USA.1,2 Approximately 70–80 % of sporadic GISTs are
caused by gain-of-function mutations in KIT, whereas 5–
10 % are caused by gene mutations, deletions, or insertions
that activate platelet-derived growth factor receptor alpha
(PDGFRα).3,4 Another 10–15 % are wild type (WT) for
KIT and PDGFRα but may contain mutations in BRAF
(including up to 15 % with the V600E mutation) or succinate
dehydrogenase (∼2 %).3–5
Surgery is the primary treatment for resectable GIST, but
this approach is not always curative. Although complete
(R0) resection can be achieved in up to 85 % of patients
with primary disease, approximately 50 % of patients devel-
op recurrences or metastases within 5 years of primary
resection.6 Thus, prior to the advent of tyrosine kinase in-
hibitor (TKI) therapy, the 5-year recurrence-free survival
(RFS) rate remained at only 45–65 %.6,7 The TKI, imatinib,
which selectively inhibits the KIT receptor, has demonstrat-
ed clinical benefit for patients with GIST. In clinical trials,
imatinib treatment resulted in response rates of 40–55 %,
improved progression-free survival (PFS) for patients with
KIT-positive unresectable or metastatic GIST,8–11 and ex-
tended RFS and overall survival (OS) in the adjuvant
setting.12,13 Accordingly, imatinib is currently approved as
first-line treatment in both settings.14
Treatment of GIST depends on several factors such as the
presence of metastases, expected difficulty of surgery, size of
the primary tumor, and overall health of the patient. The
judicious use of surgery and imatinib therapy is essential to
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maximizing patient outcomes in GIST. Herein, we discuss
how the optimal use of surgery (for primary tumors and
metastases) in combination with neoadjuvant/preoperative
and adjuvant/postoperative imatinib can improve clinical
outcomes and may extend survival.
Methods
We performed a systematic review of published medical
literature (PubMed) for English-language articles based on
the following search terms: gastrointestinal stromal tumor
(GIST); GIST and surgery; GIST and resection; GIST and
metastasectomy; GIST and imatinib; and imatinib and adju-
vant or neoadjuvant therapy. Selected relevant abstracts from
key oncology meetings were also reviewed.
GIST Presentation and Diagnosis
GISTs primarily arise in the stomach (60 %) and small
intestine (35 %), with fewer than 5 % occurring in the
esophagus, mesentery, omentum, and rectum. Rarely, cases
occur outside of the GI tract.15 Although metastases are
mostly hepatic and peritoneal-based (Fig. 1), they can also
develop extra-abdominally late in the disease.16
Small GISTs (<2 cm) are usually asymptomatic and de-
tected incidentally during endoscopy, surgery or physical
examination (21 %), or autopsy (10 %).5,17 However, most
GISTs (69 %) are diagnosed at the time of presentation with
nonspecific symptoms such as nausea, vomiting, early sati-
ety, melena and anemia (due to bleeding caused by
intraluminal erosion or intraperitoneal rupture), abdominal
pain, distension, fever, or leukocytosis.5,18
GISTs originate in the muscularis propria, likely originat-
ing from the interstitial cells of Cajal. Most GISTs present as a
single endophytic or exophytic nodule with a well-defined
border and a median size of 3–5 cm (range of a few millime-
ters to ≥35 cm).5 They rarely invade adjacent structures, but
penetration through the bowel wall, organ invasion,
adenopathy, cystic degeneration, irregular margins, mesenter-
ic fat infiltration, ulceration, hemorrhage, and necrosis likely
indicate malignancy. GISTs are also highly vascular (Fig. 2)
and friable. Thus, they are prone to rupture and dissemination,
which greatly increase the risk of recurrence.19
Histologically, GISTs can have spindle (70 %), epithelioid
(20 %), or mixed cellular morphologies (10 %). Because
spindle and epithelioid GISTs can be confused with many
other tumor types (e.g., leiomyoma, schwannoma, sarcomatoid
carcinoma), a suspected diagnosis of GISTshould be confirmed
by immunohistochemical staining.5 Markers typically include
KIT (c-KIT, CD117), CD34, and α-smooth muscle actin,
which stain positive in 95, 70, and 30–40 % of cases,
respectively. The discovered on GIST1 (DOG1) marker can
facilitate the diagnosis of KIT-negative GISTs since 92 % are
DOG1-positive.5,20,21
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Fig. 1 GIST metastatic spread is typically hematogenous, with metas-
tases occurring mainly to the liver (a) and peritoneum (b)
Fig. 2 Many GISTs are or become hypervascular, as shown in this patho-
logic specimen
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Imaging of GIST
Endoscopic ultrasound (EUS), computed tomography (CT)
with contrast enhancement, magnetic resonance imaging
(MRI), and positron emission tomography (PET) can be used
to image suspected GISTs, characterize extent of disease,
and assess response to therapy.
The endoscopic characteristics of GISTs include smooth
shape, normal overlying mucosa, occasional mucosal ulcer-
ation, and firm consistency on compression (Fig. 3).22 How-
ever, standard endoscopy cannot reliably determine the size
of these submucosal lesions nor provide adequate biopsy
samples using standard forceps.23 EUS can determine addi-
tional lesion features, including hypoechoic appearance,
oval shape, and wall layer of origin, which may aid in
diagnosing GIST and determining malignant features.24,25
EUS-guided tissue acquisition for histological analysis is
now preferred for GISTs because it provides adequate material
for histologic and mutational analyses,26 with a diagnostic
accuracy of ∼80 %.27–29 Moreover, endoscopic ultrasound-
guided fine-needle aspiration (EUS-FNA) is preferred over
percutaneous biopsy due to its lower risk of hemorrhage and
tumor seeding.30 More recently, the utility of endoscopic
ultrasound-guided Tru-Cut biopsy (EUS-TCB) for GISTs
was evaluated in six patients to obtain specimens for pathological
and immunohistochemical studies.31 All tumorswere >2 cm, and
core tissue samples were successfully procured in all cases.
The final diagnosis was KIT-positive GIST in five patients and
leiomyoma in one patient. No patients developed complica-
tions after the procedure, suggesting that EUS-TCB is safe.
Additionally, EUS-TCB is faster to perform than endoscopic
mucosal biopsy, providing sufficient tissue for pathological
diagnosis.31
Contrast-enhanced CT is the best radiological technique
for the characterization of GISTs and for the evaluation of the
extent of disease.32 Typically, GISTs appear as hyperdense,
enhancing masses on CT. When present, calcification, ulcer-
ation, necrosis, cystic areas, fistula, metastases, ascites, and
infiltration indicate malignancy.33 The limitations of CT
include the inability to accurately identify the bowel wall
layers involved and difficult analysis of small lesions.22 MRI
provides higher sensitivity for small liver lesions and should
be used to evaluate liver metastases or when CT is inconclu-
sive or contraindicated.34 MRI also offers good soft tissue
contrast and may be best for imaging retrorectal tumors.35
Most GI malignancies are metabolically active and take up
the radiolabeled glucose analog 18F-fluorodeoxyglucose
(18FDG), making 18FDG-PET a highly sensitive and valuable
imaging tool for diagnosis and a predictor of clinical outcome
(Fig. 4).22 The overall sensitivity of 18FDG-PET is approxi-
mately 80 % in detecting GISTs at initial presentation.20
Unfortunately, GISTs exhibit variable 18FDG uptake,36,37
and only some tumors are 18FDG-avid. 18FDG-PET is thus
typically reserved for resolving ambiguous findings on CT or
MRI (e.g., increase in size due to pseudo-progression versus
true tumor progression) and for monitoring early response to
imatinib treatment by serial scans. In phase II trials, 18FDG-
PET revealed responses within the first 1–7 days of treatment
in 69–85 % of patients, supporting its use to monitor early
response to imatinib.38,39 Decreases in FDG uptake, as mea-
sured by changes in SUVmax, can occur as early as 24 h after
imatinib treatment.20 At present, however, there are no stan-
dardized criteria for PET response for GIST, and this is an area
of active research.
Biology Dictates Treatment
Patients with suspected GIST should be evaluated by a
multidisciplinary team with expertise in sarcoma, as recom-
mended by current National Comprehensive Cancer Net-
work (NCCN) and European Society of Medical Oncology
(ESMO) guidelines. They should undergo a thorough work-
up, including imaging and biopsy (unless biopsy will not
change the decision to operate), to obtain an accurate diag-
nosis and determine the optimal treatment.14,26 The progno-
sis of patients with primary tumors varies depending upon
Fig. 3 Endoscopy image of an ulcerated proximal gastric GIST (a) and
corresponding EUS (b) (images courtesy of Dr. Thomas Savides)
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tumor size, mitotic index (MI, mitoses per 50 high-power
fields [HPF] equals 5 mm2), and location.15,40 In an analysis
of pooled, population-based cohorts involving 2,560 patients
with operable GIST, independent adverse prognostic factors
included tumor rupture and male gender, in addition to large
tumor size, high MI, and non-gastric location.41
For GISTs ≤2 cm in size, abdominal/pelvic CT and/or
MRI should be performed to determine tumor location and
possible presence of metastatic disease.14,26,30 Biopsy
should be obtained by EUS-FNA or core needle to confirm
diagnosis and identify potential high-risk features (e.g., ir-
regular border, cystic spaces, ulceration, echogenic foci,
heterogeneity, MI ≥5/50 HPF). Patients without high-risk
features may be followed up by endoscopic surveillance for
signs of transformation or until they become symptomatic.
However, all rectovaginal GISTs require biopsy/excision,
regardless of size, due to their increased risk of morbidity.30
A biopsy by endorectal EUS is also recommended to screen
for imatinib-resistant genotypes (e.g., WT GISTs, PDGFRα
D842V mutation) to avoid unnecessary drug-related toxicity
and ineffective therapy.14,26 If EUS-guided biopsy is not
feasible, laparoscopic or open resection can be performed.
For resectable GISTs >2 cm, abdominal/pelvic CT and/or
MRI are also recommended to identify potential metastases
and determine surgical risk. Resection is the preferred pri-
mary treatment for localized GISTs >2 cm, with a goal of R0
margins, intact pseudocapsule, no tumor rupture, and mini-
mal morbidity. Postsurgical pathology is important to con-
firm GIST diagnosis.14,26 The pathology report should detail
anatomic location, tumor morphology, size, MI (determined
from the most proliferative area), and the presence/absence
of tumor rupture.30
Surgical and Systemic Treatment Options
Surgical options for GISTs range from minimally invasive
endoscopic techniques for small tumors to open surgery for
large malignancies. The goal of surgical treatment for GIST is
complete gross resection (i.e., negative microscopic margins
and intact pseudocapsule without tumor rupture). Because
lymph node metastases are uncommon, lymphadenectomy is
not generally indicated. Gastric GISTs located away from the
gastroesophageal junction may be adequately resected with a
gastric wedge resection, rather than by gastrectomy with
lymphadenectomy. The lack of need for lymphadenectomies,
combined with advances in minimally invasive techniques,
has resulted in wider acceptance of minimally invasive ap-
proaches for resecting larger GISTs.42–44 Table 1 summarizes
the advantages and disadvantages of various surgical proce-
dures for GIST resection. For example, endoscopic submuco-
sal resection with negativemargins may not be attainable in all
patients, and this technique has been associated with high
rates of margin positivity and perforation, compared with
other procedures.45–49 Regardless of the chosen method, cap-
sule disruption and/or tumor rupture should be avoided during
surgery to minimize the risk of recurrence.50
Laparoscopic techniques are well-established for the re-
section of gastric GISTs ranging from a mean of 3.4 to 10 cm
without additional risk of complications or recurrence.42–44,51–57
Current guidelines suggest laparoscopy for tumors located in the
anterior wall of the stomach, jejunum, or ileum.58 Several case
reports have also shown that combined laparoscopic and endo-
scopic techniques can be used successfully to resect GISTs.59–61
Compared with laparoscopic surgery, laparotomy allows
for additional exposure, visualization, and mobilization of
larger tumors.62–64 Although no differences in recurrence
rates have been reported between laparoscopic procedures
and laparotomy, the latter has been associated with longer
postoperative hospital stays, greater blood loss, and longer
operation time. However, this may reflect a selection bias
because large tumors may not be resectable by minimally
invasive approaches.
Adjuvant Imatinib Therapy
Imatinib can further improve patient outcomes when used as
adjuvant therapy. The randomized, double-blind, placebo-
Fig. 4 18FDG-PET scan of a patient with 18FDG-avid metastatic GIST
showing significant uptake of this marker
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controlled American College of Surgeons Oncology Group
Z9001 phase III study was conducted to assess the survival
benefit of 1 year of adjuvant therapy with imatinib (400
mg/day) in patients with high risk of recurrence following
complete resection of primary GIST. Adjuvant imatinib signif-
icantly reduced GIST recurrence in patients with tumors ≥3 cm
in size: the 1-year RFS rate was 98 % with imatinib versus
83%with placebo (P<0.0001).12 Analysis at 4-year follow-up
showed no difference in RFS for patients undergoing R1
versus R0 resection, regardless of whether they received adju-
vant imatinib (hazard ratio [HR], 1.095; 95 % confidence
interval [CI], 0.66–1.82; P=0.73) or placebo (HR, 1.51;
95%CI, 0.76–2.99; P=0.24).50 These data suggest that factors
beyond margin status, such as rupture and tumor location, may
also be critical for predicting recurrence.
Subsequently, to explore whether increasing duration
of imatinib therapy would result in improved RFS at
long-term follow-up, the open-label Scandinavian Sarco-
ma Group/Sarcoma Group of the Arbeitsgemeinschaft
Internistische Onkologie (SSGXVIII/AIO) phase III trial ran-
domized patients who underwent gross resection of primary
KIT-positive GIST to receive 1 or 3 years of adjuvant imatinib
(400 mg/day). These patients were judged to be at high risk of
recurrence if they had tumors with one or more of the follow-
ing characteristics: diameter >10 cm; MI >10 mitoses per 50
HPF; tumor diameter >5 cm with >5 mitoses per HPF; or
tumor rupture before or at surgery. Patients had significantly
greater RFS and OS with 3 years adjuvant imatinib versus
1 year of treatment (Fig. 5). At 5-year follow-up, RFS and OS
rates were 65.6 and 92.0 % in the 3-year arm versus 47.9 and
81.7 % in the 1-year arm (P<0.001 and P=0.02), respectively.13
Accordingly, NCCN guidelines now recommend at least
3 years of adjuvant imatinib treatment for patients with
KIT-positive GIST who are at high risk of recurrence
based on tumor size, MI, site, rupture, and completeness
of surgery.14
The risk of GIST recurrence can be predicted based on MI,
tumor size and location, and tumor rupture. Various stratification
strategies have been developed to quantify the risk of recurrence
in patients with primary GIST.40,65–67 The 2002 National In-
stitutes of Health (NIH) Fletcher criteria66 rely solely onMI and
tumor size, whereas the Miettinen–Lasota/Armed Forces Insti-
tute of Pathology criteria40 also account for tumor location
(gastric versus duodenal versus jejunal/ileal versus rectal), de-
fining six risk groups and providing an estimated rate of metas-
tasis or tumor-related death. The modified NIH Fletcher system
defines risk by tumor size, location (gastric versus non-gastric),
MI, and tumor rupture while identifying subgroups at especially
high risk for recurrence.68 The Memorial Sloan-Kettering no-
mogram was derived from 127 patients and validated at two
additional centers. It predicts 2- and 5-year RFS after the resec-
tion of localized, primary GIST based upon tumor size, location,
and MI.65 In 2010, the American Joint Committee on Cancer
proposed a GIST staging system parallel to that for other soft
tissue sarcomas based upon tumor location (gastric versus small
intestine), tumor size (T), lymph node metastasis (N), distant
metastasis (M), and MI.69 Most recently, another method for
risk assessment was proposed by Joensuu and colleagues.41
Using an observational cohort of 2,560 patients and a validation
cohort of 920 patients who had R0/R1 resections, they devel-
oped prognostic contour maps that utilize tumor size, location
(including extraintestinal GISTs), MI, and tumor rupture to
predict 10-year RFS. Additional factors such as KIT, PDGFRα,
and BRAF mutational status and tumor histology (e.g., spindle
versus epithelioid) are being investigated, but are not currently
considered for risk assessment. However, there is no standard-
ized risk assessment strategy. Physicians who treat patients with
GIST need to ensure that these tools are used routinely and
correctly to optimize decisions on the prescription and duration
of adjuvant imatinib for eligible patients.
The optimal duration of adjuvant imatinib is still un-
known, but two ongoing studies are currently addressing
this question. The European Organization for Research and
Treatment of Cancer 62024 trial (ClinicalTrials.gov identifier:
NCT00103168) is a randomized, phase III study of 2 years of
imatinib therapy in patients with GIST at intermediate or high
Table 1 Relative advantages and disadvantages of surgical options for primary GISTs
Surgical technique Advantages Limitations
(evidence)
Tumor
location
Disadvantages
Endoscopy45–49 Minimally invasive; potentially
shorter operation time
Small series;
retrospective
study
Esophagus;
stomach;
rectum
Often leaves positive margins
Laparoscopy42–44,51–57 Full-thickness resection of stomach wall;
negative margins; minimal risk of
dissemination; shorter hospital stay
Small studies
(n=4–61)
Stomach;
small bowel
Can be technically challenging
with larger tumors
Laparoendoscopy59–61 Monitor endoscopic resection;
repair injury/perforation
Case reports Stomach;
duodenum
Laparotomy62,63 Better visualization and mobilization of larger
tumors or those in technically challenging
locations
Small case series;
retrospective
studies
Stomach Longer hospital stay;
potentially more blood loss;
potentially longer operation
time
J Gastrointest Surg (2013) 17:1997–2006 2001
risk of recurrence following resection, with a 5-year follow-
up. PERSIST-5 (ClinicalTrials.gov identifier: NCT00867113)
is a phase II trial evaluating up to 5 years of imatinib in
patients at significant risk of GIST recurrence following com-
plete resection. Results from these trials will provide addition-
al information regarding the long-term use of adjuvant
imatinib.
Neoadjuvant/Preoperative Imatinib Therapy for Locally
Advanced/Metastatic GIST
Neoadjuvant/preoperative imatinib therapy may reduce the
risk of surgical morbidity and improve the probability of
achieving complete resection. Several studies support its use
in patients with potentially resectable primary or metastatic
GIST. Tielen et al. evaluated 57 patients with locally advanced
primary GIST who received neoadjuvant imatinib for a
median 8 months.70 Imatinib caused tumor reduction (median,
49 %) and enabled R0 resection in 84 % of patients, with no
tumor rupture; 5-year PFS and OS rates were 77 and 88 %,
respectively.70 Additionally, in patients with advanced prima-
ry GIST who received neoadjuvant imatinib for up to 12
months, 11 out of 14 (79 %) subsequently underwent com-
plete resection (4-year OS, 100 %; 4-year disease-free surviv-
al, 64 %; follow-up, 48 months).71 Neoadjuvant imatinib can
also facilitate resection of borderline resectable primary
GIST.72 Thus, neoadjuvant imatinib can be employed for
treating borderline or initially unresectable tumors in the gas-
troesophageal junction, duodenum, or rectum.
In another study, 55 patients with metastatic GIST
underwent surgery after a median 16 months of TKI therapy
(range, 3–72 months).73 At the time of surgery, the rate of
tumor recurrence or progression was lower in patients who
responded to preoperative TKI therapy (48 %) than in those
who did not (85 %). Although nearly all patients who undergo
excision of metastases ultimately experience recurrence,32
initial response to combined preoperative TKI therapy and
complete resection correlated with improved PFS and OS.73
These retrospective results suggest that patients with
advanced primary or metastatic/recurrent GIST may have
improved outcomes with surgical resection if they re-
spond to neoadjuvant/preoperative imatinib as compared to
those patients who have progressive disease on therapy. Un-
fortunately, prospective trials comparing imatinib plus
surgery versus surgery alone have failed to accrue patients.
Therefore, the additional benefit of surgery over imatinib
alone is still unproven. Despite a lack of prospective data,
neoadjuvant/preoperative imatinib (starting dose, 400mg/day)
is recommended by the NCCN (duration based on tumor
response, generally 6–12 months) and ESMO guidelines as
an option in patients with large, localized GISTs in which
resection carries significant risk of morbidity/functional defi-
cit and in those with poorly positioned tumors that are mar-
ginally resectable, unresectable, recurrent, or metastatic.14,30
Presently, however, this is not an approved indication for
neoadjuvant/preoperative imatinib (or other TKIs) for GIST.
Surgical Resection of Recurrent or Metastatic GISTs
Approximately 50 % of patients who undergo GIST resection
will develop recurrent disease,6 at which time approximately
two thirds will have liver metastases and half will have peri-
toneal disease (Fig. 1).32 Liver metastases are usually multi-
focal, but approximately 25 % are candidates for resection.
Combinedwith perioperative imatinib therapy,metastasectomy
can be effective in some patients.74 In a retrospective study,
seven patients with advanced/recurrent GIST underwent rad-
ical resection of liver (n=4), peritoneum (n=1), liver and
peritoneum (n=1), or liver and lymph node (n=1) metastases
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upon best response to preoperative imatinib; imatinib was
then continued for a median of 26 months. The 2-year PFS
was 64.4 %.75
Perioperative imatinib can also improve outcomes in
metastasectomy patients who present with metastatic GIST.76
DeMatteo et al. reported increased 2-year PFS (61 %) and OS
(100 %) rates in patients with metastatic GISTwho responded
to perioperative imatinib. In contrast, 2-year PFS and OS rates
were 0 and 36 %, respectively, in patients who did not
respond.77 Another study showed that, for patients who
underwent surgical debulking in the context of perioperative
TKI therapy, the 1-year PFS rates were 80, 33, and 0 % for
patients with stable disease (SD), limited progression, and
generalized progression, respectively (P<0.0001), whereas
the 1-year OS rates were 95, 86, and 0 %, respectively
(P<0.0001).80 In another study, patients with metastatic GIST
who were treated with perioperative TKI therapy and partial
hepatectomy had an OS rate of 96.7, 76.8, and 67.9 % at 1, 2,
and 3 years, respectively. The median OS was not reached at
5 years.74 Long-term follow-up of patients with GIST who
underwent metastasectomy in the context of perioperative
imatinib treatment revealed a median OS of 8.7 years for
R0/R1 resections, compared with 5.3 years for R2 resections
(P=0.0001).78 Moreover, median survival was not reached in
R0/R1 patients with hepatic-only metastases compared with
8.7 and 5.9 years in patients with peritoneal (P=0.064) versus
peritoneal and hepatic metastases (P=0.001 and P=0.024).78
In the prospective phase II Radiation TherapyOncologyGroup
0132 trial, the safety and efficacy of neoadjuvant/preoperative
imatinib (600 mg/day for 8–12 weeks) were evaluated in
patients who underwent resection of advanced primary (group
A, n=30) or metastatic (group B, n=22) GIST, followed by
adjuvant/postoperative imatinib for 2 years.79 In group A, 7 %
of patients had a partial response (PR) and 83 % had SD,
compared with 4.5 % PR and 91% SD in group B. The 2-year
PFS rate was 83% in group Aversus 77% in group B, and the
estimated rate of OS was 93 % in group A versus 91 % in
group B. Surgical complications and imatinib toxicity were
minimal, suggesting that combining perioperative imatinib
with surgery is both feasible and safe for patients with ad-
vanced or metastatic GIST.79 At 5-year follow-up, RFS and
OS rates were 57 and 77 % in group A, respectively. Six of
seven relapses occurred after patients discontinued adjuvant
imatinib.80 In group B, PFS and OS rates were 30 and 68 %,
respectively. Six of ten relapses also occurred after discontin-
uation of adjuvant imatinib. Importantly, there was no increase
in long-term surgical complications compared with the initial
report.
Lastly, the role of surgery in patients with metastatic/recurrent
GIST who exhibited at least 6 months of SD or response while
taking imatinib has been evaluated. At a median follow-up of
58.9 months, median OS was not reached in patients who
underwent surgery (n=42), compared with 88.8 months in those
who did not undergo surgery (n=92), with PFS values of 87.7
and 42.8 months, respectively (P=0.001 for both).81
Overall, these results suggest that combining surgery with
perioperative imatinib therapy can be more effective than
either treatment alone in patients with advanced primary
GIST, as well as those with recurrent or metastatic GIST,
provided the disease is responsive to imatinib.
Future Directions and Conclusions
Technical advances now allow access to enhanced imaging
and advanced minimally invasive surgical techniques for
many patients, hence facilitating tumor visualization and
diagnosis, pathologic and mutational analyses, and treatment
to improve recovery and outcomes. Surgical decision-
making based on tumor genetics and responsiveness to TKIs
is expected to evolve further. Meanwhile, the increasing
safety51,82–85 and oncologic integrity86 of laparoscopic GIST
resections encourage further exploration of minimally
invasive options, such as robotic surgery,87–89 transanal min-
imally invasive surgery,90 and fluorescent-guided imaging
during surgery.91
Results of ongoing trials will undoubtedly provide addi-
tional insights into the synergy of surgery and imatinib
therapy and bring us closer to determining optimal treatment
regimens for patients with GIST. Regardless, current evi-
dence supports the combined use of surgery and periopera-
tive imatinib because its impact on patient outcomes can be
greater than either treatment alone. Surgical resection of
metastases may even allow prolonged or complete remission
in patients who respond to neoadjuvant imatinib and contin-
ue imatinib therapy afterwards. However, it is critical that
patients be evaluated by a multidisciplinary team with ex-
pertise in GIST to coordinate surgery and therapy, as well as
to ensure maximal clinical benefits over the entire course of
the disease.
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